# RO4929097 in Treating Patients With Recurrent Invasive Gliomas

> **NCT01269411** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01269411
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2012-02
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01269411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01269411, "RO4929097 in Treating Patients With Recurrent Invasive Gliomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01269411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*